Recent results presented at the AACR Congress show the benefit of durvalumab with chemotherapy, then as an adjuvant, in resectable NSCLC patients, confirming immunotherapy's effectiveness in both neoadjuvant and adjuvant stages.

On 14 Apr 2023, the first-in-class first-in-human phase 1 trial and translational study of the mono (ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 was reported at the AACR Congress.

On 14 Apr 2023, the first-in-human phase 1 trial of IO-108 as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors was reported at the AACR Congress.

On 15 Apr 2023, the updated PFS & OS from the interim analysis (data cutoff Oct 14, 2021) of the study (NCT03910127) was reported at the AACR Congress, illustrating its potential clinical benefits and setting the stage for further exploration.

The 2023 AACR Congress set the scene with the revelation of the latest clinical outcomes of HS-10365, a highly potent and selective RET TKI, offering significant insights into its potential therapeutic benefits.

New clinical results for Tebotelimab, a PD-1/LAG-3 dual antibody, shown at 2023 AACR, reveal promise for untreated advanced mucosal melanoma.

Interim results from a human trial on PLB-1004 presented at the 2023 AACR Congress highlight its clinical promise.

On 14 Apr 2023, the data from phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors was updated at the AACR Congress.

Preliminary findings from the phase I study on Orca-T cell therapy with tacrolimus in RIC will be presented at ASH 2023, showcasing its promise.

On Dec 11, 2023, new clinical data on zilurgisertib (INCB000928, LIMBER-104), alone or with ruxolitinib for myelofibrosis-related anemia, will be presented at ASH 2023.

On 10 Dec 2023, the 3-Year final analysis of efficacy and safety of Ruxolitinib from the phase III REACH3 study will be unveiled at the 2023 ASH Congress.

On 11 Dec 2023, the updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2) in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) will be reported in 2023 ASH.